8-K: Pacira BioSciences Announces $250 Million Convertible Notes Offering and Share Repurchase Program

Pacira BioSciences plans to offer $250 million in convertible senior notes due 2029, using proceeds for debt repurchase, capped call transactions, and share buybacks.

Summary

• Pacira BioSciences intends to offer $250 million in convertible senior notes due 2029 through a private placement.
• The company plans to grant initial purchasers an option to buy an additional $37.5 million in notes.
• A portion of the proceeds will be used to repurchase existing 2025 convertible notes, fund capped call transactions, and repurchase up to $50 million of its own shares.
• The remaining funds will be allocated for general corporate purposes, including working capital and research and development.
• The company has amended its credit agreement to allow for the share repurchase program and the proposed notes offering.
• The capped call transactions are intended to reduce potential dilution from the conversion of the new notes.
• The company has also amended its credit agreement to allow for the share repurchase program and the proposed notes offering.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is proactively managing its debt and capital structure. The offering is expected to provide funds for growth and reduce potential dilution. However, there are risks associated with market conditions and potential dilution.

Positives

• The share repurchase program could increase shareholder value.
• The capped call transactions are expected to reduce potential dilution from the convertible notes.
• The refinancing of the 2025 notes could improve the company's debt structure.
• The company is raising capital for general corporate purposes, including research and development.

Negatives

• The offering of convertible notes could lead to potential dilution of existing shares if the notes are converted.
• The company is taking on additional debt with the new convertible notes.
• The market price of Pacira's common stock could be affected by the hedging activities of the option counterparties.
• The success of the offering is subject to market conditions.

Risks

• The company may not be able to complete the proposed offering or related transactions on the anticipated terms, or at all.
• Market conditions could impact the success of the offering and the terms of the notes.
• The hedging activities of the option counterparties could cause volatility in the company's stock price.
• There is a risk of dilution if the convertible notes are converted into common stock.

Future Outlook

The company anticipates completing the proposed offering, repurchasing the 2025 notes, and repurchasing shares of its common stock, but these are subject to market conditions and customary closing conditions. The company disclaims any obligation to update these forward-looking statements.

Management Comments

• Pacira intends to use a portion of the net proceeds from the offering to repurchase a portion of its outstanding 0.750% Convertible Senior Notes due 2025.
• Pacira intends to use the remainder of the net proceeds from the offering for general corporate purposes, including working capital, and research and development expenditures.

Industry Context

This announcement reflects a common strategy for biotech companies to manage debt and capital structure, often using convertible notes to raise funds while mitigating dilution through capped call transactions. The repurchase of existing debt and shares is also a common practice to optimize capital allocation.

Comparison to Industry Standards

• Many biotech companies use convertible notes to raise capital, as seen with companies like BioMarin Pharmaceutical and Incyte Corporation.
• The use of capped call transactions is a standard practice to reduce potential dilution, similar to what is done by companies like Regeneron Pharmaceuticals.
• Share repurchase programs are also common among established biotech companies with strong cash flow, such as Amgen and Gilead Sciences.
• The size of the offering and the terms will be compared to recent similar offerings by other biotech companies to assess its competitiveness.

Stakeholder Impact

• Shareholders may experience short-term volatility in the stock price due to hedging activities.
• Shareholders may benefit from the share repurchase program.
• Noteholders will receive convertible notes with the potential for conversion into common stock.
• The company's employees may benefit from the company's continued investment in research and development.

Next Steps

• The company will negotiate the final terms of the notes with the initial purchasers.
• The company will complete the private placement of the convertible notes.
• The company will repurchase a portion of its 2025 convertible notes.
• The company will enter into capped call transactions.
• The company will repurchase up to $50 million of its common stock.

Key Dates

Keywords

convertible notes, share repurchase, capped call, debt financing, private placement, Pacira BioSciences, dilution, refinancing